RE:The difference between GLP and non-GLP Newsletter Q3 2020:
‘The Company is currently conducting non Good Laboratory Practice (“GLP”) toxicology studies with Rutherrin® to determine the maximum recommended human dose of Rutherrin®, when administered systemically into the human body, via IV injections. Theralase® has completed one animal model and is diligently working to complete the second animal model. If successful, Theralase® will commence GLP toxicology studies in 2Q2021 with an aim to commencing a Phase Ib clinical study in GBM and NSCLC in 4Q2021.’
Since GBM has been dropped we must take it that non-GLP toxicology studies in NSCLC were successful and completed 2 years` ago.